A Systematic Review on the Extent and Quality of Pharmacoeconomic Publications in Egypt

Farid, Samar; Elmahdawy, Mahmoud; Baines, Darrin

doi:10.1007/s40261-018-0730-5

Cited by 15 publications

(18 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our study involved most countries and the largest number of studies from MENA, health economic studies from the region have previously been reviewed in high-quality systematic reviews. Al-Aqeel et al [37] identified 15 health economic studies in KSA up to May 2011, Eljilany et al [4] reviewed 49 studies from countries of the Gulf Cooperation Council (Bahrain, KSA, Kuwait, Oman, Qatar, and UAE) until the end of 2017, and Farid et al [5] reviewed 15 studies from Egypt published between 2002 and 2017. While we included only studies that compared alternatives, previous reviews also included studies describing a single technology.…”

Section: Discussionmentioning

confidence: 99%

“…While we included only studies that compared alternatives, previous reviews also included studies describing a single technology. Farid et al [5] excluded studies that compared multiple countries, while we excluded studies involving nonlocal populations. Although the eligibility criteria were different, the comparison with previous reviews revealed that potentially eligible articles were not identified during our search, which is a limitation of our study.…”

Section: Discussionmentioning

confidence: 99%

“…[2,3] Despite the increasing importance of economic considerations in the allocation of resources and the delivery of healthcare, recent reviews have reported limited quality and quantity of health economic evaluations in the Gulf region [4] and Egypt. [5] Although the institutional back-ground of health technology assessment and health economic evaluation is still under development, [6][7][8][9] a number of pharmacoeconomic guidelines and expert recommendations have already been published in both high-and middle-income countries in the region. [10][11][12] However, the health economic studies in MENA as a whole have not yet been systematically reviewed.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Health Economic Publications From the Middle East and North Africa Region: A Scoping Review of the Volume and Methods of Research

Zrubka

Rashdan

Gulàcsi

2020

Global Journal on Quality and Safety in Healthcare

View full text Add to dashboard Cite

Introduction We reviewed the scope of countries, diseases, technologies, and methods involved in the health economic evaluations published in the Middle East and North Africa (MENA) region. Methods PRISMA guidelines were followed. A PubMed search was conducted up to December 15, 2019. English language full-text articles were included if they reported original research on humans; involved the local population from Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates, or Yemen; reported costs; and involved a full or partial health economic analysis comparing alternative health technologies. Data on publication year, country of origin, disease area according to ICD-10, type of health technology, and applied methods were extracted. Results From 105 eligible articles, 57.1% were published between 2015 and 2019. Egypt (30.5%) and Saudi Arabia (27.6%) were the most frequently involved countries. Infectious diseases were most often studied (27.6%). The assessed technology was a system (eg, infection control, screening, coverage/access, hospital management, or healthcare delivery program) in 41.9% of studies. Cost-utility analysis (CUA) was the most frequent method (29.5%) and was growing rapidly. Health system perspective was adopted in 52.4% of studies, whereas societal perspective was scarce (8.6%). The majority of studies (46.7%) were published in Scimago Q1 journals. Over half of the studies (54.2%) did not report or did not have a funding source. Conclusions From 2015, health economic analysis became more frequent in the MENA region, providing input to value-based health policy and financing. For further growth, in addition to the development of the institutional background, valid and more standardized local cost and outcome data should be available.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Health Economic Publications From the Middle East and North Africa Region: A Scoping Review of the Volume and Methods of Research

Zrubka

Rashdan

Gulàcsi

2020

Global Journal on Quality and Safety in Healthcare

View full text Add to dashboard Cite

show abstract

“…A foundational step in designing capacity development programmes is to conduct a needs assessment, understood as "the systematic study of a problem or innovation, incorporating data and opinions from varied sources, in order to make effective decisions or recommendations about what should happen next" [6]. Available reviews of the health economic literature conducted in the region, be they with a cross-country [7,8] or single-country focus [9,10], all suggest a limited use of economic evaluation and substantial scope for improving methodological quality. There are also indications that most pharmacy schools offer pharmacoeconomics courses as part of their curriculum, albeit with widely varying hours and topics [11].…”

Section: Introductionmentioning

confidence: 99%

Capacity for health economics research and practice in Jordan, Lebanon, the occupied Palestinian territories and Turkey: needs assessment and options for development

Gheorghe

Gad

Ismail

et al. 2020

Health Res Policy Sys

View full text Add to dashboard Cite

Background: Capacity for health economics analysis and research is indispensable for evidence-informed allocations of scarce health resources; however, little is known about the experience and capacity strengthening preferences of academics and practitioners in the Eastern Mediterranean region. This study aimed to assess the needs for strengthening health economics capacity in Jordan, Lebanon, the occupied Palestinian territories and Turkey as part of the Research for Health in Conflict in the Middle East and North Africa (R4HC) project. Methods: We combined a bibliometric analysis of health economics outputs based on a literature search conducted across seven databases with an online survey of academic researchers and non-academic practitioners. The records included in the bibliometric analysis were original studies and reviews with an explicit economic outcome related to health, disease or disability, had at least one author in Jordan, Lebanon, Palestine or Turkey, and were published between January 2014 and December 2018. Two types of analyses were conducted using VOSviewer software, namely keyword co-occurrence and co-publication networks across countries and organisations. The online survey asked academic researchers, analysts and decision-makersidentified through the bibliometric analysis and regional professional networksabout previous exposure to and priorities for capacity development in health economics. Results: Of 15,185 records returned by the literature search, 566 were included in the bibliometric analysis. Organisations in Turkey contributed more than 80% of records and had the broadest and most diverse network of collaborators, nationally and internationally. Only 1% (n = 7) of studies were collaborations between researchers in two or more different jurisdictions. Cost analysis, cost-effectiveness analysis and health system economics were the main health economics topics across the included studies. Economic evaluations, measuring the economic burden of disease and health equity, were reported by survey respondents (n = 80) as the most important areas to develop in. Short courses, learn-by-doing and mentoring from an experienced professional were, in aggregate, the most preferred learning styles.

show abstract

“…Despite recognizing this need, it has been very challenging to implement Health Technology Assessment due to a fragmented healthcare system and limited database on health outcomes and diseases prevalence [6,10]. Furthermore and to our knowledge, country speci c EQ5D value set has not been determined in Lebanon and outcomes of interventions have been based on surrogate endpoints and factors related to health determinants without implementing the HRQOL instrument measures [11][12][13][14]. While this latter has been widely used to capture not only scienti c but also social aspects on an interventions to guide decision makers in setting priority when choosing among alternative interventions (Rowen et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Health Related Quality of Life in Patients with Chronic Disease in Lebanese Community Setting

Dimassi¹,

Nasser²,

Issa³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The impact of chronic diseases on patient quality of life are becoming of high priority in healthcare system. There is an increased need of such data in Middle Eastern countries. Objective: To measure health related quality of life (HRQOL) in patients with chronic disease to associate this information with demographic data, socioeconomic status, and health satisfaction.Setting: Six community pharmacies in Beirut region.Method: A prospective cross-sectional study was conducted to gather information on socioeconomic status, health condition and quality of life of participants during their visit to their local pharmacy. Main outcome measure: Health related quality of life using the EQ5D instrumentResults: Participants (n=103) gave an average of 6.8, and 7.4 over ten for their current health and for their satisfaction with their treatment, respectively. The mean utility score was 0.762 (SD 0.202). The number of prescribed medications per respondent indicated a significant impact on HRQOL (p = 0.002); with diuretic agents having a significant difference in utility scores (p<0.001). On average, participants 75 years or older, hospitalized in the past 12 months, diagnosed with hypertension, had a lower utility score of 0.15 (p<0.001), 0.111 (p=0.001), and 0.065 (p=0.035), respectively. For every unit increase in treatment satisfaction, the quality of life score increased by 0.036 unit (p= 0.001)Conclusion: HRQOL as measured by the EQ5D in this study was affected in patients with cardiac disease or diabetes. Male gender, advanced age, low socioeconomic status, frequent hospital and doctor visits were important risk factors for a poor HRQOL.

show abstract

A Systematic Review on the Extent and Quality of Pharmacoeconomic Publications in Egypt

Cited by 15 publications

References 35 publications

Health Economic Publications From the Middle East and North Africa Region: A Scoping Review of the Volume and Methods of Research

Health Economic Publications From the Middle East and North Africa Region: A Scoping Review of the Volume and Methods of Research

Capacity for health economics research and practice in Jordan, Lebanon, the occupied Palestinian territories and Turkey: needs assessment and options for development

Health Related Quality of Life in Patients with Chronic Disease in Lebanese Community Setting

Contact Info

Product

Resources

About